News
Press Releases

Monday, November 21, 2016

Clinical Trials for Alzheimer’s Disease (CTAD) Selects Stemedica International to Present at Annual International Conference

San Diego, California and Lausanne, Switzerland — November 21, 2016 Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s disease (AD), is pleased to announce it will share its latest preclinical at the International Conference on Clinical Trials for Alzheimer’s Disease (CTAD).  The 9th annual CTAD will be held December…
Read Entire Article

Tuesday, November 1, 2016

University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica’s Stem Cells for Alzheimer’s disease

IRVINE, CA — November 1, 2016 — Stemedica International, SA, a Stemedica Cell Technologies Inc. subsidiary that uses its proprietary allogeneic stem-cell therapies for Alzheimer’s disease, announces enrollment of its first patient at the University of California, Irvine (UCI). The study, is entitled “A Phase IIa Multicenter, Randomized, Single-blind, Placebo-controlled, Crossover Study to Assess the…
Read Entire Article

Wednesday, October 26, 2016

University of California Irvine (UCI) Doses First Patient in Phase IIa Clinical Trial Using Stemedica’s Stem Cells for Alzheimer’s disease

Lausanne, Switzerland — October 26, 2016 Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s disease (AD), is pleased to announce it will share its latest preclinical data at the Society for Neuroscience 46th Annual Conference held from November 12-16 in San Diego, CA. SfN’s annual meeting is the premier…
Read Entire Article

Wednesday, July 27, 2016

STEMEDICA BEGINS FIRST CLINICAL TRIALS IN THE U.S. USING ADULT ALLOGENEIC STEM CELLS TO TREAT ALZHEIMER’S DISEASE

San Diego, California, and Lausanne, Switzerland Stemedica Cell Technologies, Inc. and its subsidiary, Stemedica International S.A., a leader in the development of innovative stem cell-based treatments for Alzheimer’s disease (AD), are pleased to announce the opening of enrollment into a new study at Emory University in Atlanta and University of California, Irvine (UCI). The study…
Read Entire Article

Wednesday, March 23, 2016

Stemedica International Presents at Geneva Springfield Alzheimer’s Conference in Athens, Greece

Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that its Chief Scientist, Tristan Bolmont, PhD, gave a presentation at the 14th International Athens / Springfield Symposium on Advances in Alzheimer Therapy on Saturday, March 12, 2016 in Athens, Greece. This prestigious symposium drew over 1000 participants from…
Read Entire Article

Wednesday, February 24, 2016

Stemedica International Receives Approval from Emory University to Initiate Alzheimer’s Disease Study with Adult Allogeneic Stem Cells

Lausanne, Switzerland — February 24, 2016 — Stemedica International, SA, a leader in the development of innovative stem cell-based treatments for Alzheimer’s Disease announced today that it has received IRB approval from Emory University in Atlanta, Georgia to initiate a clinical study entitled, “A Phase IIa Multicenter, Randomized, Single-blind, Placebo-controlled, Crossover Study to Assess the…
Read Entire Article

Tuesday, November 10, 2015

Stemedica Establishes Stem Cell Commercial Manufacturing Facility

San Diego, California and Epalinges, Switzerland – November 10, 2015 – Stemedica Cell Technologies, Inc., a leading manufacturer of adult, allogeneic stem cells and preserved stem cell proteins, has signed, through its subsidiary Stemedica International SA, an agreement with Smith & Nephew to take over its commercial grade cell manufacturing facility in Lausanne, Switzerland. The…
Read Entire Article

Wednesday, August 26, 2015

Stemedica International and EPFL Awarded Swiss Government Grant for Diabetes and Stem Cell Research

Epalinges, Switzerland — August 26, 2015 — Stemedica International, a subsidiary of Stemedica Cell Technologies, Inc. (San Diego, CA) and its academic partner, École Polytechnique Fédérale de Lausanne (EPFL) have been awarded a research grant by the Swiss Commission for Technology and Innovation (CTI). The value of the project is CHF 708,000 (approx. 750,000 USD)….
Read Entire Article

Tuesday, June 9, 2015

FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s itMSC Therapy to Treat Alzheimer’s Disease

SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica Cell Technologies, Inc. received the FDA’s investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer’s disease (AD), the sixth leading cause of death in…
Read Entire Article

Tuesday, August 19, 2014

Stemedica International Announces Pre-clinical Data of its Alzheimer’s Study

Epalinges, Switzerland – Aug. 19, 2014 – Stemedica International S.A., a Stemedica Cell Technologies Inc. subsidiary developing stem cell therapies for Alzheimer’s disease and dementia, revealed the first results of an intravenous administration of allogeneic, human, ischemia-tolerant mesenchymal stem cells (itMSCs) in a pre-clinical animal model of Alzheimer’s disease. The results demonstrated a greater than 30-percent…
Read Entire Article
Older Entries »